In a following phase Ib clinical trial, vantictumab in combination with paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer had shown decent tolerance and promising efficacy (Diamond et al., 2020). The gene discussed is ERBB2; the disease is breast cancer.